49 results about "TNM Staging" patented technology

The invention aims to provide a reagent capable of detecting the expression condition of a target protein in a paraffin-embedded tissue, and particularly provides a kit used for evaluating the prognosis information of a patient suffering from the esophageal squamous cell carcinoma. The kit comprises antibodies of the three target proteins, namely Annexin II, Kindlin-2 and Myosin-9, and further comprises goat serum, 0.01 M citrate repair liquid, 3% H2O2, a Polymer reinforcing agent, a Polymer, a DAB color reagent and a PBS solution. The kit can be used for evaluating the prognosis of the patient; compared with the international TNM staging, the kit is simpler and easier to use, and higher in both sensitivity and specificity, and is more suitable for the prognosis evaluation of Chinese suffering from the esophageal squamous cell carcinoma.

The present invention provides a system for accurately predicting the prognosis of gastric cancer patients. The system is based on the Nomogram prognostic prediction model constructed by the present invention. Compared with the traditional TNM staging system, the system has high accuracy, individualized prediction, and conforms to Prognostic features of gastric cancer with Chinese characteristics.

The invention discloses a multi-scale technology-based tumor texture feature extraction method. The method includes the following steps that: tumor PET image data are obtained from clinic, an ideal tumor treatment region is drawn; segmentation is carried out according to the boundary of the drawn target region, and gross tumor volume (GTV) is extracted, and PET images only containing the GTV are obtained; gray level quantization is performed on each PET image, and two-dimensional dual-tree complex wavelet transform is performed on the quantized images, and a plurality of sub-band images can be obtained from each image; all the sub-band images which are obtained by decomposing the PET images are re-combined into new stereo GTV; the mean and variance of a detail coefficient matrix obtained after two-dimensional dual-tree complex wavelet transform are calculated, and tumor texture feature values are calculated; and the relationships among the maximum values (SUVmax) of the tumor texture feature values and standardized uptake values, tumor TNM stages and infiltration depth are established, and the heterogeneous texture feature values of a quantized tumor are screened and optimized.

The invention relates to the field of bioengineering and tumor markers, in particular to a marker for locally advanced esophageal squamous cell carcinoma prognosis and an application of the marker. The marker is a combined marker consisting of one or more of miR-135b-5p, miR-139-5p, miR-29c-5p and miR-338-3p, and locally advanced esophageal squamous cell carcinoma prognosis is predicted by detecting expression levels of the four miRNA in tumor tissue and performing calculation according to a formula (0.4690*miR-135b-5p expression level)+(0.3839*miR-139-5p expression level)+(0.1733*miR-29c-5p expression level)+(0.3368*miR-338-3p expression level). The combined marker has the advantages of good stability and high sensitivity and specificity and can more accurately and more valuably evaluateprognosis of patients than traditional clinical pathological factors such as TNM (tumor-node-metastasis) staging and the like. On one hand, the molecular marker related to esophageal squamous cell carcinoma prognosis is provided, on the other hand, an esophageal squamous cell carcinoma prognosis prediction model is established, so that individual treatment of esophageal squamous cell carcinoma isrealized, the comprehensive treatment level of the esophageal squamous cell carcinoma is improved, the life quality of esophageal squamous cell carcinoma patients is improved, and the lifetime of theesophageal squamous cell carcinoma patients is prolonged.

The invention belongs to the field of genetic engineering and in particular relates to an application of a bile exosome long and non-coding RNA (lncRNA) ENST00000588480.1 in diagnosis of bile duct carcinoma, prognostic prediction and target spot drug treatment, wherein the long and non-coding RNA is positively correlated with TNM staging and poor prognosis of a patient.

The to-be solved technical problem of the invention is to provide a reagent for detecting the expression situation of target protein in a paraffin-embedded tissue. The technical scheme for solving the technical problem is to provide a kit for evaluating prognosis information of an esophagus cancer patient. The kit comprises four antibodies of target protein, and the four antibodies comprise delta-catenin, Dynamin-2, Erbin and LAP-1, and the kit also comprises goat serum, 0.01 M citrate restoration liquid, 3% H2O2, a Polymer reinforcing agent, a polymer, a DAB chromogenic reagent and a PBS solution. The kit can help to relatively simply practicably evaluate prognosis of esophagus cancer patients compared with an international TNM staging method, and is higher in both sensitivity and specificity compared with the TNM staging method, and is relatively suitable for esophagus cancer prognosis evaluation of countrymen.

The invention relates to the technical field of lung cancer gene detection, in particular to an ANXA3 gene or an ANXA3 protein as a biomarker of lung adenocarcinoma. Research findings, ANXA3 gene wasabnormally expressed in lung adenocarcinoma in both Xuanwei and non-Xuanwei areas. The expression of ANXA3 gene was lower or higher than normal level. ANXA3 gene or protein could be used as biomarkerof lung adenocarcinoma to diagnose lung adenocarcinoma, judge lymph node metastasis, assist TNM staging and prognosis. The invention provides an ANXA3 gene and an expression product thereof in preparation for prejudging whether lymph node metastasis of lung adenocarcinoma, The present invention provides a new diagnostic method for clinically diagnosing metastasis of lung adenocarcinoma and provides a new candidate drug for treating metastasis of lung adenocarcinoma. The present invention relates to a method for treating metastasis of lung adenocarcinoma and a pharmaceutical composition for treating lung adenocarcinoma.

The invention discloses the application of NFI transcription factors in esophageal squamous cell carcinoma, and particularly relates to the application of a transcription factor NFIB in the diagnosisof esophageal squamous cell carcinoma and the application of a transcription factor NFIA in evaluating the differentiation degree, TNM staging and prognosis of esophageal squamous cell carcinoma. Thelevel of the NFI transcription factors of esophageal squamous cell carcinoma is detected and analyzed by the immunohistochemical technique, it is found that patients with high expression of NFIA havea low tumor differentiation degree, a high TNM stage and poor prognosis, and high expression of NFIB corresponds to a low esophageal squamous cell carcinoma tissue differentiation degree, in this way,a new way is provided for the diagnosis and prognosis judgment of esophageal squamous cell carcinoma, and a reference is provided for clinicians to analyze the condition of patients with esophageal squamous cell carcinoma.

The invention belongs to the technical field of cell biology, and relates to application of Netrin-4 in preparing a preparation for detecting stomach cancer and a prognosis marker. Experiments display that Ntn4 is combined with a ligand neogenin thereof to activate cancer promoting paths such as Jak / Stat, PI3K / Akt and ERK / MAPK, thereby achieving the effects of promoting gastric cancer cell proliferation and invasion. Experiment results show that Ntn4 has remarkable high expression in both a serum sample and a tumor tissue sample of a patient with gastric cancer, high expression is in negative correlation with the lifetime of the patient and in positive correlation with TNM staging, it shows that Ntn4 can be used as potential serological indicator for gastric cancer and prognosis and used for preparing the preparation for detecting stomach cancer and the prognosis marker. The preparation comprises a reagent and a kit which are used for detecting stomach cancer and the prognosis marker.

The invention relates to an esophageal squamous cell carcinoma microenvironmental cell marker molecular model and application thereof. The molecular model mainly comprises a-SMA+ (invasive frontier) fibroblasts, CD163+ (interstitial) macrophages, CD117+ (protogenic layer) mastocytes and CD117+ (invasion frontier) mastocytes. The molecular model can be used to predict the prognosis of patients withesophageal squamous carcinoma and group adjuvant treatment sensitivity groups. A kit mainly includes an anti-CD117 protein antibody, an anti-CD163 protein antibody and an anti-a-SMA protein antibody.According to the invention, the combination of three molecules combined with histopathological features predicts patients' prognosis, which has a higher predictive effect than single index detectionand clearly distinguishes patients with esophageal squamous carcinoma adjuvant treatment sensitivity; an immune tissue chemical hypersensitivity two-step method on which the molecular model is based is a mature and reliable method which can be widely used in primary hospitals; and compared with international TNM staging, the molecular model has a higher predictive effect, and is simpler, easier, more sensitive and more specific.

The invention discloses a kit for detecting expression condition of a paraffin embedding operative specimen of an esophagus cancer patient and further predicting prognosis of the patient by combining 5-lipoxygenase metabolic pathway protein antibodies. The kit comprises three target protein antibodies: 5-LO, FLAP and LTA4H antibodies, and also comprises goat serum, 0.01M citrate repair liquid, 3% H2O2, a Polymer enhancer, a Polymer polymer, a DAB chromogenic reagent and PBS solution. Compared with single index detection, the kit for predicting the prognosis of the patient by combining 5-lipoxygenase metabolic pathway proteins has higher prediction effect, ranking only second to prediction ability of TNM staging. Moreover, the immunohistochemical ultrasensitive two-step method in the invention is a mature and reliable method which can be widely used in primary hospitals.

A “malignancy-risk” (MR) gene signature score was developed with abundant proliferative genes using principal component analysis. This MR gene signature was shown to be a predictive and prognostic factor of overall survival in early-stage NSCLC. The malignancy-risk signature showed a significant association with OS, with poor survival seen in patients having a higher MR score and better survival seen in patients having a low MR score. As a prognostic factor, the MR gene signature showed a positive correlation with TNM stage, histologic grade, and smoking status. Combination of the MR signature with each clinical parameter often showed the best survival in the low MR group with good clinical outcome. The MR gene profile, tested with a PCA scoring method, discriminated overall survival in lung cancer patients was a predictor independent of pathological staging and other clinical parameters.

The invention discloses an application of ABHD6 in diagnosis, prognosis and treatment products of non-small cell lung cancer. The invention discloses a monoacylglycerol hydrolase ABHD6 (alpha / beta-hydrolase-domain-containing 6). The results of tissue microarray showed that the expression of ABHD6 in tumor tissues was significantly higher than that in adjacent tissues, and the high expression of ABHD6 was related to lymph node metastasis and TNM staging in non-small cell lung cancer, which was an independent factor of poor prognosis in NSCLC. The application of ABHD6 in diagnosis, prognosis andtreatment products of non-small cell lung cancer can influence the invasion and migration of non-small cell lung cancer cells in vitro by silencing ABHD6, and can slow down the growth speed of the tumor and slow down the process of the tumor migration to the lung.

The invention discloses a lung cancer TNM staging acquisition method. The method comprises the following steps of identifying a target nodule in a medical image; acquiring long and short paths of thetarget nodule, and generating T stages at least based on the long and short path; identifying abnormal lymph nodes in the medical image, and generating N stages by judging whether the abnormal lymph nodes have metastasis or not; acquiring whether the target nodule has distant metastasis or not, and generating M stages according to whether the target nodule has distant metastasis or not; and generating a TNM stage according to the T stage, the N stage and the M stage. According to the method, a nodule recognition model, a nodule segmentation model and a lymph node metastasis recognition model are trained, the information outputted by the models is utilized to automatically generate a T stage and an N stage, and whether distant metastasis information is generated into an M stage or not is judged in combination with doctor input or by accessing medical records and the like. According to the method, TNM staging generation efficiency is effectively improved, a doctor can conveniently and quickly know the illness state of a patient, and diagnosis efficiency is improved.

The invention provides a staining kit for all pathological tissue sections (especially lung cancer TNM staging) and a use method thereof. According to the staining kit and the use method thereof, immunohistochemical staining and special staining are combined for application, two staining modes can be completed on the same slice, staining time is shortened, displayed information amount is far larger than signals and information amount provided by traditional separate single staining, missed diagnosis of tiny infiltration is avoided, effective help can be provided for clinical later treatment, an important diagnosis basis is provided for defining clinical stages of a patient, and whether vascular tumor embolism exists in other types of tumors or not can be accurately judged. If other types of markers are selected, the markers can also be used as an index for cardiovascular disease discrimination.

The invention relates to the technical field of biological medicine, and provides a molecular marker for prognosis prediction of esophageal squamous cell carcinoma and application thereof. An RNA-seq data set is used for screening out four circular RNA gene combinations with the maximum AUC value, and the four circular RNA gene combinations are named as 4-circular RNA markers. The study shows that the 4-circular RNA markers can independently predict the survival of ESCC patients; the accuracy of the traditional TNM staging evaluation on the ESCC patient prognosis is obviously improved; and the 4-circular RNA markers can be used as reference judging indexes of the esophageal squamous cell carcinoma prognosis survival time and prognosis survival risk prediction reference. Through studying the relationship between the 4-circular RNA markers and the clinical prognosis of the esophageal squamous cell carcinoma patients, a novel marker is provided for the esophageal squamous cell carcinoma prognosis judgment, so that the timely intervention treatment on the esophageal squamous cell carcinoma patients can be improved; the clinical prognosis of the patients is improved; and the important significance is realized in the clinical practice.

The invention provides a kit for detecting the prognosis of patients with esophageal squamous cell carcinoma in the Xinjiang region. The kit comprises a phospholipase epsilon 1 protein, an IKB alpha protein and a mutant P53 protein. The kit also comprises a citrate buffer solution with the content of 0.01M, an ethylenediaminetetraacetic acid repair solution with the content of 10mM, a H2O2 solution with the mass concentration of 3%, a phosphate buffer solution with the content of 0.01M, a BSA blocking solution with the mass concentration of 5%, an immunohistochemical Envision kit and a DAB developing reagent. The kit can forecast the prognosis of patients through detecting the expression case of the paraffin-embedded surgical specimen of the patients with esophageal squamous cell carcinomathrough PLCE1, IKB alpha and P53 proteins. Compared with the existing kit realizing single index detection, the kit has higher prediction effects and has the prediction ability similar to the TNM staged prediction ability. The two-step immunohistochemical method using the kit is a mature and reliable method that can be widely used in primary hospitals.

The invention aims at providing a reagent for detecting the interest protein expression condition in paraffin-embedded tissue. According to the technical scheme, a detection kit for evaluating prognosis information of an esophageal squamous carcinoma patient is provided. The kit comprises antibody primary antibody CD105 protein, esVEGFR2 protein and MYC protein antibodies for resisting three kinds of interest protein, and further comprises goat serum, 0.01M citrate restoration liquid, 3% H2O2, a Polymer enhancer, a Polymer, a DAB color reagent and a PBS solution. The kit can be used for evaluating prognosis of the esophageal squamous carcinoma patient, and is simpler than international TNM staging and easy to carry out, the sensibility and specificity of the kit are both higher than those of TNM staging, and the kit is more suitable for esophageal squamous carcinoma prognosis evaluation of Chinese.

The invention discloses an oesophagogastric junction adenocarcinoma related biomarker and application thereof. The biomarker is NFIB. The invention discloses application of NFIB in diagnosis of oesophagogastric junction adenocarcinoma, and application of NFIB in predicting lymph node metastasis, TNM staging, and prognosis of the oesophagogastric junction adenocarcinoma; the invention further provides a kit for diagnosis of the oesophagogastric junction adenocarcinoma, and a kit for predicting the lymph node metastasis, the TNM staging, and the prognosis of the oesophagogastric junction adenocarcinoma.

The invention discloses a lung cancer TNM staging acquisition method and device. The method includes identifying a first target nodule in a first medical image; matching the first target nodule in a second medical image, and obtaining a second target nodule in the second medical image; acquiring long and short diameters of the second target nodule, and generating T stages at least according to thelong and short diameters of the second target nodule; identifying abnormal lymph nodes in the first medical image and generating N stages by judging whether the abnormal lymph nodes have metastasis or not; identifying whether the first target nodule in the first medical image has distant metastasis or not, and generating M stages according to whether the first target nodule has distant metastasisor not; and generating a TNM stage according to the T stage, the N stage and the M stage; wherein the first medical image and the second medical image are different modal medical images for the samepatient and the same part. According to the scheme, the TNM staging generation efficiency is effectively improved, doctors can conveniently and quickly know the illness state of a patient, and the diagnosis efficiency is improved.

The invention relates to new application of TRIM66 protein, particularly application of TRIM66 protein in preparing a non-small cell lung cancer prognosis evaluation reagent or kit. The invention detects the expression rate of the TRIM66 in non-small cell lung cancer tissues is 70.5% which is higher than 51.4% of the para-carcinoma tissues. The invention detects the TRIM66 is related to the tumor size, depth of invasion, lymphatic metastasis and TNM staging of the non-small cell lung cancer, and the size of tumor, lymphatic metastasis, TNM staging and TRIM66 are independent factors for evaluating prognosis of the patients with non-small cell lung cancer. The invention also detects that the interference with the TRIM66 expression can inhibit the A549 cell proliferation.

The invention discloses a gastric cancer prognosis prediction device, which belongs to the technical field of medical images. The device comprises a first acquisition module, a second acquisition module and a determination module, wherein the first acquisition module isused for acquiring a gastric cancer digital pathological image corresponding to a gastric cancer tissue slice to be detected; the second acquisition module is used for acquiring inter-cell distance information on the gastric cancer digital pathological image, and the inter-cell distance information is used for indicating the tightness degree between different immune cells; and the determination module is used for determining a prognosis prediction result corresponding to the gastric cancer tissue slice according to the intercellular distance information. According to the embodiment of the invention, the gastric cancer prognosis is predicted based on the inter-cell distance information, and compared with a traditional TNM staging prognosis judgment device, the prediction effect of the gastric cancer prognosis is ensured.

The invention belongs to the fields of function and application of genes and RNA, and relates to application of an MACC1-AS1 probe to preparation of a diagnostic reagent for predicting clinical prognosis of gastric cancer. The invention also provides a diagnostic kit for predicting clinical prognosis of gastric cancer. The kit comprises the MACC1-AS1 probe. The invention discloses that in the gastric cancer, the MACC1-AS1 is related to the prognosis of a patient suffering from the gastric cancer and is in positive correlation with clinical staging and TNM staging of the patient for the first time; and the MACC1-AS1 is an important molecule which generates anti-oxidation substances to maintain redox balance, promotes glycolysis to maintain glycometabolism, maintains survival and reduces apoptosis when the gastric cancer cells do not have sugar stress. Therefore, the invention provides theoretical basis and clinic basis for research of clinical prognosis related factors of the patient suffering from the gastric cancer and clinical application of non-coding RNA.

The invention is a kit for detecting the expression of paraffin-embedded surgical specimens of patients with esophageal cancer in combination with 5-lipoxygenase metabolic pathway protein antibodies, and then predicting the prognosis of patients. The kit includes antibodies ‑5‑LO, FLAP, and LTA4H antibodies for 3 target proteins, as well as goat serum, 0.01M citrate repair solution, 3% H2O2, Polymer enhancer, Polymer polymer, DAB chromogenic reagent, PBS solution. However, the kit of 5-lipoxygenase metabolic pathway protein used in the present invention to jointly predict the patient's prognosis has a higher predictive effect than single index detection, second only to the predictive ability of TNM staging, and the immune tissue based on the present invention The chemical hypersensitivity two-step method is a mature and reliable method that can be widely used in primary hospitals.

The invention provides a system for precisely predicting prognoses of patients with gastro-entero-pancreatic neuroendocrine tumors. The system is based on a Nomogram prognosis prediction model constructed by the invention; the system has the characteristics of high precision and individualized prediction, and conforms to gastro-entero-pancreatic neuroendocrine tumors prognosis prediction with Chinese characteristics compared with a traditional TNM (Tumor-node-metastasis) staging system. Meanwhile, the system has good guidance effect on selection of patient individualized treatment strategies,design of new drug clinical tests and standardization of consistency of the enrolled patients in clinical work.

Provided is an invention and application of a PTEN Nedd8 modification as a new marker for breast cancer and a specific antibody of the modification. The invention provides application of the Nedd8 modification at the PTEN protein site K402 as the marker in preparing a product used for judging grading and staging of the breast cancer, and application in preparing a product used for predicting breast cancer prognosis. The PTEN Nedd8 modification antibody is further prepared, the PTEN Nedd8 modification antibody can specifically identify the Nedd8 modification at the PTEN site K402, the PTEN Nedd8 modification is enhanced along with increasing of the TNM staging and pathological grading of the tumor malignancy of a breast cancer patient, and the higher the PTEN Nedd8 modification degree is, the poorer the patient's prognosis is. The invention has an important clinical significance for predicting the prognosis conditions of the breast cancer and providing an adjuvant treatment scheme for an individual patient.

The invention provides a pull-out scale device for international TNM staging of esophageal squamous cell carcinoma, which is composed of a rectangular hollow sleeve with openings at both ends and a pumping plate marked with staging results. The pumping plate is inserted into the hollow sleeve. The cover is suitable, and there are a first rectangular window and a second rectangular window on the front of the hollow cover, and a semicircular notch is provided in the middle of the two ends of the opening of the central control cover to facilitate the movement of the pumping plate. On the back and front of the hollow sleeve, relevant definitions of each staging variable are printed. The present invention is displayed in the form of an intuitive ruler, helps clinicians to accurately and quickly stage, and is conducive to remembering new stage regulations as soon as possible. Adjuvant treatment is recommended as early as possible for patients with late stage, and the most appropriate comprehensive treatment plan should be selected. At the same time, strengthen postoperative follow-up monitoring, timely detection of local and distant metastasis, and prolong survival. And it is convenient to make a better treatment plan in the follow-up, and form an objective index that is helpful to effectively evaluate the curative effect.

The invention discloses a biomarker for evaluating the therapeutic effect of esophageal squamous cell carcinoma (ESCC) neoadjuvant chemoradiotherapy (nCRT) and application of an MMP12 protein as the biomarker in preparation of a reagent, kit or detection device for evaluating the rapeutic effect of ESCC nCRT. The abnormal expression level of MMP12 is significantly related to TNM staging, lymph node metastasis and survival time (P is less than 0.05) of ESCC, a new biomarker for predicting nCRT response of an ESCC patient is determined through microarray data analysis, and the MMP12 may be a useful tumor biomarker and a treatment target for the ESCC patient.

The invention belongs to the technical field of biology, and relates to application of phosphatase PHLPP2 as a biomarker, in particular to an application of PHLPP2 in preparation of a prognostic marker preparation for treating pancreatic cancer through vitamin C. The PH structural domain of the phosphatase is rich in leucine repeat protein phosphatase 2, and corresponding conserved sites of Akt, RAF1 and the like can be directly dephosphorylated, so that cell apoptosis is promoted, and cell proliferation and migration are inhibited; the tests show that the expression level of the PHLPP2 is reduced, the killing effect of the vitamin C on pancreatic cancer tumors can be inhibited, the high expression of the PHLPP2 is positively related to the lifetime of a patient and is negatively related to TNM staging, and the PHLPP2 can be used as a potential biomarker of the vitamin C for treating the pancreatic cancer and is further used for preparing a prognosis marker preparation of the vitamin C for treating the pancreatic cancer.

The invention relates to the technical field of biological medicine, in particular to a marker for prognosis prediction of colon cancer, and a model construction method and system. According to the TLS-related quantitative index for prognosis prediction of the colon cancer patient, the TLS-related quantitative index is used as a marker for prognosis prediction of the colon cancer, the immune state of the patient can be reflected more accurately and objectively, and higher prognosis prediction accuracy is achieved. The invention further provides a colon cancer prognosis risk model and a construction method thereof, the model can carry out prognosis prediction independent of TNM staging, prognosis risk layering can be better carried out on colon cancer patients compared with TNM staging, more targeted treatment schemes can be made for patients with different prognosis clinically, and precise medical treatment can be achieved.